Terutroban
drug drugOn this page
Also known as S18886Triplion
Summary
Terutroban (CHEMBL2107786) is a phase-3 clinical-stage small molecule targeting TBXA2R.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 1 (TBXA2R)
- Chemistry: 407.9 Da · C20H22ClNO4S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107786 |
| Name | Terutroban |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 9938840 |
| Molecular formula | C20H22ClNO4S |
| Molecular weight | 407.9 |
| InChIKey | HWEOXFSBSQIWSY-MRXNPFEDSA-N |
SMILES: CC1=C(C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1)CCC(=O)O
IUPAC name: 3-[(6R)-6-[(4-chlorophenyl)sulfonylamino]-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid
Also known as: S18886, Terutroban, Triplion, TERUTROBAN
Patent coverage: 153 distinct patent families (387 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 346 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| TBXA2R | TP receptor | Antagonist | 6.49 | 0.2% | P21731 |
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Thromboxane A2 receptor.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| TBXA2R | 7.79 | IC50 | 16.4 | nM | CHEMBL_ACT_15105492 |
Target pathways
Aggregated over 1 target gene(s): TBXA2R.
Top Reactome pathways
13 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Hemostasis | 1 | TBXA2R |
| Signal Transduction | 1 | TBXA2R |
| Signaling by GPCR | 1 | TBXA2R |
| Class A/1 (Rhodopsin-like receptors) | 1 | TBXA2R |
| GPCR downstream signalling | 1 | TBXA2R |
| Eicosanoid ligand-binding receptors | 1 | TBXA2R |
| Prostanoid ligand receptors | 1 | TBXA2R |
| Signal amplification | 1 | TBXA2R |
| G alpha (q) signalling events | 1 | TBXA2R |
| G alpha (12/13) signalling events | 1 | TBXA2R |
| Thromboxane signalling through TP receptor | 1 | TBXA2R |
| GPCR ligand binding | 1 | TBXA2R |
| Platelet activation, signaling and aggregation | 1 | TBXA2R |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| smooth muscle contraction | 1 |
| inflammatory response | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| response to nutrient | 1 |
| response to xenobiotic stimulus | 1 |
| positive regulation of blood coagulation | 1 |
| response to testosterone | 1 |
| response to ethanol | 1 |
| positive regulation of angiogenesis | 1 |
| positive regulation of blood pressure | 1 |
| positive regulation of vasoconstriction | 1 |
| positive regulation of smooth muscle contraction | 1 |
| cellular response to lipopolysaccharide | 1 |
Indications & clinical
Indications
0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
284 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| DESLORATADINE | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| DIHYDROERGOTAMINE | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| ESTRADIOL VALERATE | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| OLANZAPINE | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| PIMAVANSERIN | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| POMALIDOMIDE | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| RIFAMPIN | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| TEGASEROD | ChEMBL + PubChem | Phase 4 (approved) | TBXA2R |
| ACETYLCHOLINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| AMSACRINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | TBXA2R |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | TBXA2R |
| AXITINIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| BECLOMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | TBXA2R |
| BENZBROMARONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| BENZIODARONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| BEXAROTENE | ChEMBL | Phase 4 (approved) | TBXA2R |
| BITHIONOL | ChEMBL | Phase 4 (approved) | TBXA2R |
| BROMOCRIPTINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| BROMODIPHENHYDRAMINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| CABOZANTINIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | TBXA2R |
| CANNABIDIOL | ChEMBL | Phase 4 (approved) | TBXA2R |
| CERIVASTATIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| CHLORMADINONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| CHLORPROTHIXENE | ChEMBL | Phase 4 (approved) | TBXA2R |
| CHOLECALCIFEROL | ChEMBL | Phase 4 (approved) | TBXA2R |
| CICLOPIROX | ChEMBL | Phase 4 (approved) | TBXA2R |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | TBXA2R |
| COBIMETINIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| CYPROHEPTADINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| DELAVIRDINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| DEOXYCHOLIC ACID | ChEMBL | Phase 4 (approved) | TBXA2R |
| DEXAMETHASONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| DEXTROTHYROXINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | TBXA2R |
| DINOPROST | ChEMBL | Phase 4 (approved) | TBXA2R |
| DINOPROSTONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| DOXAZOSIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| DRONEDARONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| DUVELISIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| DYDROGESTERONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| ENASIDENIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| ENOXACIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| ENZALUTAMIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| EPALRESTAT | ChEMBL | Phase 4 (approved) | TBXA2R |
| EPIRUBICIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| ESTRADIOL | ChEMBL | Phase 4 (approved) | TBXA2R |
| ETHINYL ESTRADIOL | ChEMBL | Phase 4 (approved) | TBXA2R |
| EZETIMIBE | ChEMBL | Phase 4 (approved) | TBXA2R |
| FELODIPINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| FIPEXIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| FLIBANSERIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| FLUPIRTINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| FLUTAMIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| FLUTRIMAZOLE | ChEMBL | Phase 4 (approved) | TBXA2R |
| FLUVASTATIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| GLAFENINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| GLIMEPIRIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| GUANABENZ | ChEMBL | Phase 4 (approved) | TBXA2R |
| HEXACHLOROPHENE | ChEMBL | Phase 4 (approved) | TBXA2R |
| HEXESTROL | ChEMBL | Phase 4 (approved) | TBXA2R |
| IBRUTINIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| IDEBENONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| INDOCYANINE GREEN ACID FORM | ChEMBL | Phase 4 (approved) | TBXA2R |
| INDOMETHACIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| IOPANOIC ACID | ChEMBL | Phase 4 (approved) | TBXA2R |
| ISOCONAZOLE | ChEMBL | Phase 4 (approved) | TBXA2R |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| IVACAFTOR | ChEMBL | Phase 4 (approved) | TBXA2R |
| LANSOPRAZOLE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LAROPIPRANT | ChEMBL | Phase 4 (approved) | TBXA2R |
| LENVATINIB | ChEMBL | Phase 4 (approved) | TBXA2R |
| LEVAMLODIPINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LEVOMEPROMAZINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LOMITAPIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LOPERAMIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LOPINAVIR | ChEMBL | Phase 4 (approved) | TBXA2R |
| LORATADINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LOSARTAN | ChEMBL | Phase 4 (approved) | TBXA2R |
| LOVASTATIN | ChEMBL | Phase 4 (approved) | TBXA2R |
| LOXAPINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LURASIDONE | ChEMBL | Phase 4 (approved) | TBXA2R |
| LUSUTROMBOPAG | ChEMBL | Phase 4 (approved) | TBXA2R |
| MASOPROCOL | ChEMBL | Phase 4 (approved) | TBXA2R |
| MECLOFENAMIC ACID | ChEMBL | Phase 4 (approved) | TBXA2R |
| METHACHOLINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| METHIXENE | ChEMBL | Phase 4 (approved) | TBXA2R |
| METHYLPROMAZINE | ChEMBL | Phase 4 (approved) | TBXA2R |
| METHYSERGIDE | ChEMBL | Phase 4 (approved) | TBXA2R |
| MIBEFRADIL | ChEMBL | Phase 4 (approved) | TBXA2R |
Related Atlas pages
- Genes: TBXA2R
- Drugs: Clozapine, Desloratadine, Dihydroergotamine, Estradiol Valerate, Olanzapine, Pimavanserin, Pomalidomide, Regorafenib, Rifampin, Tegaserod, Acetylcholine, Amitriptyline, Amlodipine, Amsacrine, Aripiprazole, Astemizole, Axitinib, Beclomethasone Dipropionate, Benzbromarone, Benziodarone, Bexarotene, Bithionol, Bromocriptine, Bromodiphenhydramine, Cabozantinib, Candesartan Cilexetil, Cannabidiol, Cerivastatin, Chlormadinone, Chlorprothixene, Cholecalciferol, Ciclopirox, Cisapride, Clomipramine, Clotrimazole, Cobimetinib, Cyproheptadine, Daunorubicin, Delavirdine, Deoxycholic Acid, Dexamethasone, Dextrothyroxine, Diethylstilbestrol, Dinoprost, Dinoprostone, Doxazosin, Doxorubicin, Dronedarone, Duvelisib, Dydrogesterone, Enasidenib, Enoxacin, Enzalutamide, Epalrestat, Epirubicin, Estradiol, Ethinyl Estradiol, Ezetimibe, Felodipine, Fipexide, Flibanserin, Flupirtine, Flutamide, Flutrimazole, Fluvastatin, Glafenine, Glimepiride, Guanabenz, Hexachlorophene, Hexestrol, Ibrutinib, Idebenone, Indocyanine Green Acid Form, Indomethacin, Iopanoic Acid, Isoconazole, Isradipine, Ivacaftor, Lansoprazole, Laropiprant, Lenvatinib, Levamlodipine, Levomepromazine, Lomitapide, Loperamide, Lopinavir, Loratadine, Losartan, Lovastatin, Loxapine, Lurasidone, Lusutrombopag, Masoprocol, Meclofenamic Acid, Methacholine, Methixene, Methylpromazine, Methysergide, Mibefradil